Drew, Yvette
Ledermann, Jonathan
Hall, Geoff
Rea, Daniel
Glasspool, Ros
Highley, Martin
Jayson, Gordon
Sludden, Julieann
Murray, James
Jamieson, David
Halford, Sarah
Acton, Gary
Backholer, Zoe
Mangano, Raffaella
Boddy, Alan
Curtin, Nicola
Plummer, Ruth
Article History
Received: 14 May 2015
Revised: 2 December 2015
Accepted: 25 January 2016
First Online: 22 March 2016
Change Date: 26 May 2015
Change Type: Correction
Change Details: Updated online 26 May 2016: This article was originally published under a CC BY-NC-SA 4.0 license, but has now been made available under a CC BY 4.0 license. The PDF and HTML versions of the paper have been modified accordingly
Competing interests
: Nicola Curtin is an inventor on patents relating to the therapeutic use of rucaparib in combination with chemotherapy and as single agent. She has previously received research funding from Agouron for the development of rucaparib, Pfizer for preclinical studies relating to the use of rucaparib in translational studies, and Clovis Oncology for preclinical studies concerning the persistence of PARP inhibition by rucaparib. She is not currently in receipt of any financial support from these companies. Ruth Plummer is an inventor on patents relating to the use of rucaparib and has received an honorarium from Clovis Oncology in 2014. Yvette Drew has acted as an advisory board member for Clovis Oncology in 2015 and for this received an honorarium from Clovis Oncology. The remaining authors declare no conflict of interest.